Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AFATINIB vs VECTIBIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.
Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.
First-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations,Treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy,Off-label: Use in other EGFR-mutant cancers (e.g., head and neck cancer, colorectal cancer) with specific mutations
Metastatic colorectal cancer (m CRC) with wild-type RAS (KRAS and NRAS) as first-line in combination with FOLFOX or as monotherapy after progression,Metastatic colorectal cancer (m CRC) with wild-type RAS as second-line in combination with irinotecan or as monotherapy after failure of irinotecan-based regimens
40 mg orally once daily, continuously.
6 mg/kg IV every 14 days.
Terminal half-life is approximately 37 hours; supports once-daily dosing with steady-state achieved within 8 days.
Terminal half-life approximately 7.5 days (range 3.6–10.9 days); supports every-2-week dosing regimen.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP3A4-independent pathways including flavin-containing monooxygenase (FMO). Excretion mainly via feces (85%) and urine (4%) as unchanged drug and metabolites.
Primarily eliminated via the reticuloendothelial system; not metabolized by cytochrome P450 enzymes; no significant hepatic metabolism.
Primarily fecal (85%) as unchanged drug and metabolites; renal excretion accounts for <4% of the dose.
Primarily eliminated via the reticuloendothelial system; <3% excreted unchanged in urine; no significant renal or biliary elimination.
Approximately 95% bound to plasma proteins, primarily to albumin.
Approximately 95% bound, primarily to albumin; minimal binding to other plasma proteins.
Volume of distribution is approximately 2300 L (about 33 L/kg for a 70 kg individual), indicating extensive tissue distribution.
Volume of distribution approximately 3.0–4.0 L/kg; suggests extensive tissue distribution and binding to EGFR-expressing cells.
Oral bioavailability is approximately 92% relative to an oral solution; food reduces exposure, so take on an empty stomach.
Subcutaneous: Absolute bioavailability approximately 93% relative to intravenous administration.
No starting dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to safety concerns.
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (Cr Cl <30 m L/min) or ESRD.
Child-Pugh A: 40 mg once daily. Child-Pugh B: Reduce dose to 30 mg once daily. Child-Pugh C: Not recommended due to lack of data.
No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Insufficient data for severe (Child-Pugh C) hepatic impairment.
Safety and efficacy not established in pediatric patients; no specific dosing recommendations.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment recommended based on age alone; monitor renal function and tolerability, as elderly patients may have decreased renal function or comorbidities.
No specific dose adjustment recommended; no significant differences in safety or efficacy observed in patients ≥65 years compared to younger adults.
None.
None.
Severe diarrhea (including dehydration and acute kidney injury),Interstitial lung disease (ILD)/pneumonitis,Severe hepatotoxicity (elevated liver enzymes, hepatitis),Left ventricular dysfunction (assess LVEF at baseline and during treatment),Severe bullous, blistering, and exfoliative skin reactions (e.g., Stevens-Johnson syndrome),Gastrointestinal perforation,Ocular toxicities (keratitis, conjunctivitis),Renal toxicity (proteinuria, nephrotic syndrome),Fetal harm (embryo-fetal toxicity),Drug interactions with CYP3A4 inducers or inhibitors
Infusion reactions (including severe and fatal), dermatologic toxicity (including severe acneiform dermatitis and infections), increased toxicity with concurrent chemotherapy (especially diarrhea and dehydration), pulmonary fibrosis, hypomagnesemia, ocular toxicity, and potential for fetal harm.
None reported,Relative contraindications: pre-existing severe hepatic impairment, severe renal impairment, pregnancy, and breastfeeding
None known.
Take on an empty stomach (at least 1 hour before or 2 hours after food). Avoid grapefruit, grapefruit juice, and Seville oranges as they may alter drug metabolism. High-fat meals reduce absorption.
No specific food interactions are reported. However, because diarrhoea is common, patients may need to adjust their diet to manage symptoms (e.g., avoid high-fiber, fatty, or spicy foods). Adequate hydration and electrolyte replacement are essential if diarrhoea occurs. No restrictions on grapefruit juice or other CYP3A4 substrates; VECTIBIX is not metabolized by CYP enzymes.
Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neural tube defects based on animal studies showing embryotoxicity and teratogenicity at doses below human exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and impaired renal function due to inhibition of EGFR signaling critical for fetal development.
Pregnancy Category C. Panitumumab is an Ig G2 monoclonal antibody; Ig G crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EGFR inhibition, there is potential for fetal harm. Animal studies (cynomolgus monkeys) with panitumumab at doses 0.5 to 5 times the clinical exposure (AUC) revealed embryotoxicity and developmental delays (e.g., skeletal malformations, increased abortions). No adequate human studies exist. Use only if potential benefit justifies risk; avoid in pregnancy unless absolutely necessary.
No human data on afatinib excretion in breast milk; however, animal studies indicate drug presence in milk. M/P ratio is unknown. Due to potential for serious adverse effects in breastfed infants, breastfeeding is contraindicated during therapy and for at least 2 weeks after the last dose.
No data on presence in human milk, effects on breastfed infant, or milk production. Human Ig G is excreted in breast milk, but panitumumab is a large protein likely degraded in infant GI tract. M/P ratio unknown. Because of potential for serious adverse reactions in nursing infants, advise women to discontinue breastfeeding during treatment and for 2 months after last dose.
No specific dosing guidelines for pregnancy. Pharmacokinetic changes (increased volume of distribution, altered metabolism) may occur but studies have not established dose adjustments. The drug should be avoided in pregnancy unless benefit outweighs risk; if used, consider therapeutic drug monitoring if available.
No pharmacokinetic data in pregnancy; no established dose adjustments. Usual dose: 6 mg/kg IV every 14 days. If used during pregnancy, monitor maternal toxicities closely (e.g., skin, electrolytes) and consider dose reduction or discontinuation based on toxicity. No specific dose modification guidelines exist for pregnancy.
Monitor for diarrhea, which can be severe; consider loperamide and hydration. Assess for interstitial lung disease (ILD) and hepatotoxicity. Dose reduction required for severe renal impairment (Cr Cl 15–29 m L/min). For patients with EGFR exon 19 deletion or exon 21 L858R mutation, first-line use improves PFS. Avoid P-glycoprotein strong inducers (e.g., rifampin) during treatment.
VECTIBIX (panitumumab) is a fully human monoclonal antibody targeting EGFR. It is indicated for RAS wild-type metastatic colorectal cancer (m CRC). Always confirm RAS wild-type status (no mutations in KRAS/NRAS) before initiation. Infusion reactions are common; premedicate with antihistamine and acetaminophen for first dose. Monitor for dermatologic toxicity (rash, paronychia, dry skin) which is a class effect and may correlate with efficacy. Electrolyte abnormalities, particularly hypomagnesemia, can occur; monitor serum magnesium weekly during therapy and for 8 weeks after completion. Avoid use in patients with RAS mutant tumors due to lack of benefit and potential harm. VECTIBIX is not effective in tumors with BRAF V600E mutation.
Take afatinib at least 1 hour before or 2 hours after a meal.,Do not crush, chew, or split tablets; swallow whole with water.,Seek medical help for severe or persistent diarrhea, cough, or difficulty breathing.,Avoid grapefruit and Seville oranges during treatment.,Report signs of liver problems (yellowing skin/eyes, dark urine).,Use effective contraception during and for 2 weeks after stopping therapy.,Avoid direct sunlight exposure; use sunscreen.
This medication targets the epidermal growth factor receptor (EGFR) on cancer cells and is used for metastatic colorectal cancer with a specific genetic profile (RAS wild-type).,You will need genetic testing for RAS mutations (KRAS/NRAS) before starting treatment to ensure the drug is appropriate.,Common side effects include skin rash, dry skin, itching, nail infections, and diarrhea. The skin rash may be a sign the drug is working but requires management.,Report any signs of infusion reaction (chills, fever, shortness of breath, flushing) during or after the infusion.,Serious side effects include severe infusion reactions, lung inflammation (interstitial lung disease), and low magnesium levels (muscle cramps, fatigue, irregular heartbeat). You will have regular blood tests to monitor magnesium and other electrolytes.,Avoid sun exposure and use sunscreen, as the drug increases skin sensitivity to sunlight.,Drink plenty of fluids to prevent dehydration from diarrhea, and notify your doctor if diarrhea is severe or persistent.,Do not receive any vaccines without consulting your doctor, especially live vaccines.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding. Effective contraception should be used during treatment and for at least 2 months after the last dose.
"Afatinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), both undergo metabolism via CYP450 enzymes. Afatinib is a moderate inhibitor of CYP2D6 and may also inhibit CYP1A2 and CYP3A4, while fluvoxamine is a known inhibitor of CYP1A2 and CYP2C19. Coadministration can lead to increased fluvoxamine concentrations due to inhibition of its metabolism, potentially resulting in enhanced serotonergic effects such as serotonin syndrome, as well as increased adverse effects like nausea, dizziness, or QT prolongation."
"The combination of afatinib, a tyrosine kinase inhibitor, with pantoprazole, a proton pump inhibitor (PPI), can lead to reduced absorption of afatinib due to elevated gastric pH. Afatinib exhibits pH-dependent solubility, and higher gastric pH decreases its dissolution and bioavailability, potentially reducing its therapeutic efficacy. This interaction may result in suboptimal plasma concentrations of afatinib, increasing the risk of treatment failure in patients with non-small cell lung cancer."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AFATINIB vs VECTIBIX, answered by our medical review team.
AFATINIB is a Tyrosine Kinase Inhibitor Antineoplastic that works by Afatinib is an irreversible, covalent-binding inhibitor of the Erb B family of tyrosine kinases, including EGFR (Erb B1), HER2 (Erb B2), Erb B3, and Erb B4. It blocks downstream signaling pathways such as PI3K/AKT and MAPK, leading to inhibition of tumor cell proliferation and survival.. VECTIBIX is a Antineoplastic Monoclonal Antibody that works by Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AFATINIB and VECTIBIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AFATINIB is: 40 mg orally once daily, continuously.. The standard adult dose of VECTIBIX is: 6 mg/kg IV every 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AFATINIB and VECTIBIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AFATINIB is classified as Category C. Afatinib is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac, skeletal, and neura. VECTIBIX is classified as Category C. Pregnancy Category C. Panitumumab is an IgG2 monoclonal antibody; IgG crosses the placenta, with the highest transfer occurring in the third trimester. Based on its mechanism of EG. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.